Pineal region glioblastomas display features of diffuse midline and non-midline gliomas

被引:12
|
作者
D'Amico, Randy S. [1 ]
Zanazzi, George [2 ]
Wu, Peter [1 ]
Canoll, Peter [2 ]
Bruce, Jeffrey N. [1 ]
机构
[1] Columbia Univ, Med Ctr, Dept Neurol Surg, New York, NY 10027 USA
[2] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA
关键词
Pineal tumor; Pineal gland; Pineal glioma; Glioblastoma; Brain tumor; Histone H3 K27M; 3RD VENTRICULOSTOMY; PARENCHYMAL TUMORS; ENDOSCOPIC BIOPSY; MULTIFORME; MANAGEMENT; RESECTION; CLASSIFICATION; DISSEMINATION; TEMOZOLOMIDE; EXPERIENCE;
D O I
10.1007/s11060-018-2931-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pineal region glioblastomas (GBM) are very rare, with approximately 46 cases described in the literature. The epidemiology, pathogenesis, and treatment of these lesions are poorly characterized. We identified all cases of pineal region GBM treated surgically at our institution between 1990 and 2017. Demographic and clinical follow-up data were extracted from the medical records for all cases. Pathology was reviewed and classified according to 2016 World Health Organization (WHO) criteria. Specific attention was given to the frequency of histone H3 K27M mutations in these midline gliomas. Eight patients (seven men, one woman) with pineal region GBM, WHO grade IV, were identified. The most common presenting symptoms were headache (75%), vision changes (75%), and gait imbalance/ataxia (50%). Median age at diagnosis was 48.5 years (range 36-74 years). Radical subtotal resection, via a supracerebellar infratentorial approach, was achieved in 75% of patients. Review of the surgical pathology revealed seven primary GBMs (including one giant cell GBM) and one pineal region GBM that developed three years after resection of a pineal parenchymal tumor of intermediate differentiation. No cases demonstrated evidence of IDH-1 R132H mutation (N = 6) or 1p/19q co-deletion (N = 3). One case tested positive for the histone H3 K27M-mutation. Targeted exome sequencing of 467 cancer-related genes revealed nonsense mutations in ATRX and NF1. Adjuvant radiation and chemotherapy was employed in 87.5% and 75.0% of patients, respectively. Median overall survival (OS) was 15 months (range 2-24 months) from GBM diagnosis. This study expands the clinical and pathologic spectrum of pineal region GBM, and provides the first report of the genetic landscape of these tumors.
引用
收藏
页码:63 / 73
页数:11
相关论文
共 50 条
  • [21] Midline and Paramedian Supracerebellar Infratentorial Approach to The Pineal Region: A Comparative Clinical Study in 112 Patients
    Choque-Velasquez, Joham
    Resendiz-Nieves, Julio
    Jahromi, Behnam Rezai
    Colasanti, Roberto
    Baluszek, Szymon
    Muhammad, Sajjad
    Hernesniemi, Juha
    WORLD NEUROSURGERY, 2020, 137 : E194 - E207
  • [22] A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen
    Kast, Richard E.
    Michael, Alex P.
    Sardi, Iacopo
    Burns, Terry C.
    Heiland, Tim
    Karpel-Massler, Georg
    Kamar, Francois G.
    Halatsch, Marc-Eric
    BRAIN SCIENCES, 2020, 10 (01)
  • [23] Endoscopic Midline and Paramedian Supracerebellar Infratentorial Approaches to Pineal Region Tumors: A Clinical Study and Approach Comparison
    Xie, Tao
    Qu, Chenghui
    Zhang, Xiaobiao
    Yang, Qiaoqiao
    Yeh, Yuyang
    Li, Chen
    Liu, Tengfei
    Liu, Shuang
    Li, Zeyang
    Hu, Fan
    Yang, Liangliang
    Yang, Hantao
    WORLD NEUROSURGERY, 2022, 168 : 63 - 73
  • [24] Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity
    Lopez-Perez, Carlos Axel
    Franco-Mojica, Xochitl
    Villanueva-Gaona, Ricardo
    Diaz-Alba, Alexandra
    Rodriguez-Florido, Marco Antonio
    Navarro, Victor Garcia
    JOURNAL OF NEURO-ONCOLOGY, 2022, 158 (03) : 369 - 378
  • [25] The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies
    Persson, Mika L.
    Douglas, Alicia M.
    Alvaro, Frank
    Faridi, Pouya
    Larsen, Martin R.
    Alonso, Marta M.
    Vitanza, Nicholas A.
    Dun, Matthew D.
    NEURO-ONCOLOGY, 2022, 24 (09) : 1408 - 1422
  • [26] Successful treatment of non-midline primary malignant germ cell tumors with yolk sac components in neonates: report of 2 cases
    Weil, Alexander G.
    Mathews, Natalie
    Farmer, Jean-Pierre
    St Martin, Christine
    Albrecht, Steffen
    Jabado, Nada
    Dudley, Roy W. R.
    JOURNAL OF NEUROSURGERY-PEDIATRICS, 2021, 27 (01) : 47 - 51
  • [27] Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation
    Aboian, M. S.
    Solomon, D. A.
    Felton, E.
    Mabray, M. C.
    Villanueva-Meyer, J. E.
    Mueller, S.
    Cha, S.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2017, 38 (04) : 795 - 800
  • [28] Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas
    Vazaios, Konstantinos
    Lopez, Patricia Hernandez
    Aarts-Riemens, Tineke
    Daudeij, Annet
    Kemp, Vera
    Hoeben, Rob C.
    Straetemans, Trudy
    Hulleman, Esther
    Calkoen, Friso G.
    van der Lugt, Jasper
    Kuball, Juergen
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [29] Molecular and clinical characterization of H3 K27M-mutant "non-midline" glioblastoma: A case report and literature review
    Onishi, Shumpei
    Ohba, Shinji
    Kuraoka, Kazuya
    Kurashige, Takashi
    Sugiyama, Kazuhiko
    Yamasaki, Fumiyuki
    NEUROCIRUGIA, 2022, 33 (06): : 356 - 360
  • [30] Diffusion and perfusion imaging biomarkers of H3 K27M mutation status in diffuse midline gliomas
    Kathrani, Nihar
    Chauhan, Richa Singh
    Kotwal, Abhishek
    Kulanthaivelu, Karthik
    Bhat, Maya Dattatraya
    Saini, Jitender
    Prasad, Chandrajit
    Chakrabarti, Dhritiman
    Santosh, Vani
    Uppar, Alok Mohan
    Srinivas, Dwarakanath
    NEURORADIOLOGY, 2022, 64 (08) : 1519 - 1528